EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Prashasti Agrawal; Kevin A. David; Zhengming Chen; Suchitra Sundaram; Seo Hyun Kim; Ryan Vaca; Yong Lin; Samuel Singer; Mary Kate Malecek; Jordan Carter; Adam Zayac; Myung Sun Kim; Nishitha Reddy; Douglas Ney; Alma Habib; Christopher Strouse; Jerome Graber; Veronika Bachanova; Sidra Salman; Jean A. Vendiola; Nasheed Hossain; Mazie Tsang; Ajay Major; Maher K. Gandhi; Colm Keane; David A. Bond; Matthew Folstad; Julie Chang; Angel Mier-Hicks; Pallawi Torka; Priya Rajakumar; Parameswaran Venugopal; Stephanie Berg; Michael Glantz; Samuel A. Goldlust; Rahul Matnani; Pallavi Kumar; Thomas A. Ollila; Johnny Cai; Stephen E. Spurgeon; Alex G. Sieg; Joseph Cleveland; Narendranath Epperla; Reem Karmali; Seema Naik; Sonali M. Smith; James L. Rubenstein; Brad S. Kahl; Amy Chadburn; Andrew M. Evens; Peter Martin

doi:10.1080/10428194.2023.2191152

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Prashasti Agrawal, Kevin A. David, Zhengming Chen, Suchitra Sundaram, Seo Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean A. VendiolaNasheed Hossain, Mazie Tsang, Ajay Major, Maher K. Gandhi, Colm Keane, David A. Bond, Matthew Folstad, Julie Chang, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A. Goldlust, Rahul Matnani, Pallavi Kumar, Thomas A. Ollila, Johnny Cai, Stephen E. Spurgeon, Alex G. Sieg, Joseph Cleveland, Narendranath Epperla, Reem Karmali, Seema Naik, Sonali M. Smith, James L. Rubenstein, Brad S. Kahl, Amy Chadburn, Andrew M. Evens, Peter Martin

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, and immunosuppressive treatment correlated highly with EBV-positivity. EBV + tumors were associated with absent C-MYC and BCL6 expression. EBV + PTLD was more likely to be associated with the absence of CD5 expression. EBV + non-PTLD had better median OS (not reached) compared to EBV + PTLD (10.8 months) and EBV-negative patients (43 months). Multivariable Cox regression analysis showed that age, performance status, and PTLD were negative predictors of OS. EBV status and immunosuppressive treatment were not correlated with OS. Our findings merit further investigation of EBV + PCNSL tumors and EBV-directed therapies.

Original language	English (US)
Pages (from-to)	1026-1034
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	64
Issue number	5
DOIs	https://doi.org/10.1080/10428194.2023.2191152
State	Published - 2023

Keywords

Epstein-Barr virus (EBV)
post-transplant Lymphoproliferative Disorders (PTLD)
primary CNS lymphoma (PCNSL)

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2023.2191152

Cite this

Agrawal, P., David, K. A., Chen, Z., Sundaram, S., Kim, S. H., Vaca, R., Lin, Y., Singer, S., Malecek, M. K., Carter, J., Zayac, A., Kim, M. S., Reddy, N., Ney, D., Habib, A., Strouse, C., Graber, J., Bachanova, V., Salman, S., ... Martin, P. (2023). EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia and Lymphoma, 64(5), 1026-1034. https://doi.org/10.1080/10428194.2023.2191152

Agrawal, P, David, KA, Chen, Z, Sundaram, S, Kim, SH, Vaca, R, Lin, Y, Singer, S, Malecek, MK, Carter, J, Zayac, A, Kim, MS, Reddy, N, Ney, D, Habib, A, Strouse, C, Graber, J, Bachanova, V, Salman, S, Vendiola, JA, Hossain, N, Tsang, M, Major, A, Gandhi, MK, Keane, C, Bond, DA, Folstad, M, Chang, J, Mier-Hicks, A, Torka, P, Rajakumar, P, Venugopal, P, Berg, S, Glantz, M, Goldlust, SA, Matnani, R, Kumar, P, Ollila, TA, Cai, J, Spurgeon, SE, Sieg, AG, Cleveland, J, Epperla, N, Karmali, R, Naik, S, Smith, SM, Rubenstein, JL, Kahl, BS, Chadburn, A, Evens, AM & Martin, P 2023, 'EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort', Leukemia and Lymphoma, vol. 64, no. 5, pp. 1026-1034. https://doi.org/10.1080/10428194.2023.2191152

@article{94f53c9f1fc54337a01e3d61fd4f81d0,

title = "EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort",

abstract = "The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, and immunosuppressive treatment correlated highly with EBV-positivity. EBV + tumors were associated with absent C-MYC and BCL6 expression. EBV + PTLD was more likely to be associated with the absence of CD5 expression. EBV + non-PTLD had better median OS (not reached) compared to EBV + PTLD (10.8 months) and EBV-negative patients (43 months). Multivariable Cox regression analysis showed that age, performance status, and PTLD were negative predictors of OS. EBV status and immunosuppressive treatment were not correlated with OS. Our findings merit further investigation of EBV + PCNSL tumors and EBV-directed therapies.",

keywords = "Epstein-Barr virus (EBV), post-transplant Lymphoproliferative Disorders (PTLD), primary CNS lymphoma (PCNSL)",

author = "Prashasti Agrawal and David, {Kevin A.} and Zhengming Chen and Suchitra Sundaram and Kim, {Seo Hyun} and Ryan Vaca and Yong Lin and Samuel Singer and Malecek, {Mary Kate} and Jordan Carter and Adam Zayac and Kim, {Myung Sun} and Nishitha Reddy and Douglas Ney and Alma Habib and Christopher Strouse and Jerome Graber and Veronika Bachanova and Sidra Salman and Vendiola, {Jean A.} and Nasheed Hossain and Mazie Tsang and Ajay Major and Gandhi, {Maher K.} and Colm Keane and Bond, {David A.} and Matthew Folstad and Julie Chang and Angel Mier-Hicks and Pallawi Torka and Priya Rajakumar and Parameswaran Venugopal and Stephanie Berg and Michael Glantz and Goldlust, {Samuel A.} and Rahul Matnani and Pallavi Kumar and Ollila, {Thomas A.} and Johnny Cai and Spurgeon, {Stephen E.} and Sieg, {Alex G.} and Joseph Cleveland and Narendranath Epperla and Reem Karmali and Seema Naik and Smith, {Sonali M.} and Rubenstein, {James L.} and Kahl, {Brad S.} and Amy Chadburn and Evens, {Andrew M.} and Peter Martin",

note = "Publisher Copyright: {\textcopyright} 2023 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

doi = "10.1080/10428194.2023.2191152",

language = "English (US)",

volume = "64",

pages = "1026--1034",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - EBV-positive PCNSL in older patients

T2 - incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

AU - Agrawal, Prashasti

AU - David, Kevin A.

AU - Chen, Zhengming

AU - Sundaram, Suchitra

AU - Kim, Seo Hyun

AU - Vaca, Ryan

AU - Lin, Yong

AU - Singer, Samuel

AU - Malecek, Mary Kate

AU - Carter, Jordan

AU - Zayac, Adam

AU - Kim, Myung Sun

AU - Reddy, Nishitha

AU - Ney, Douglas

AU - Habib, Alma

AU - Strouse, Christopher

AU - Graber, Jerome

AU - Bachanova, Veronika

AU - Salman, Sidra

AU - Vendiola, Jean A.

AU - Hossain, Nasheed

AU - Tsang, Mazie

AU - Major, Ajay

AU - Gandhi, Maher K.

AU - Keane, Colm

AU - Bond, David A.

AU - Folstad, Matthew

AU - Chang, Julie

AU - Mier-Hicks, Angel

AU - Torka, Pallawi

AU - Rajakumar, Priya

AU - Venugopal, Parameswaran

AU - Berg, Stephanie

AU - Glantz, Michael

AU - Goldlust, Samuel A.

AU - Matnani, Rahul

AU - Kumar, Pallavi

AU - Ollila, Thomas A.

AU - Cai, Johnny

AU - Spurgeon, Stephen E.

AU - Sieg, Alex G.

AU - Cleveland, Joseph

AU - Epperla, Narendranath

AU - Karmali, Reem

AU - Naik, Seema

AU - Smith, Sonali M.

AU - Rubenstein, James L.

AU - Kahl, Brad S.

AU - Chadburn, Amy

AU - Evens, Andrew M.

AU - Martin, Peter

PY - 2023

Y1 - 2023

N2 - The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, and immunosuppressive treatment correlated highly with EBV-positivity. EBV + tumors were associated with absent C-MYC and BCL6 expression. EBV + PTLD was more likely to be associated with the absence of CD5 expression. EBV + non-PTLD had better median OS (not reached) compared to EBV + PTLD (10.8 months) and EBV-negative patients (43 months). Multivariable Cox regression analysis showed that age, performance status, and PTLD were negative predictors of OS. EBV status and immunosuppressive treatment were not correlated with OS. Our findings merit further investigation of EBV + PCNSL tumors and EBV-directed therapies.

AB - The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, and immunosuppressive treatment correlated highly with EBV-positivity. EBV + tumors were associated with absent C-MYC and BCL6 expression. EBV + PTLD was more likely to be associated with the absence of CD5 expression. EBV + non-PTLD had better median OS (not reached) compared to EBV + PTLD (10.8 months) and EBV-negative patients (43 months). Multivariable Cox regression analysis showed that age, performance status, and PTLD were negative predictors of OS. EBV status and immunosuppressive treatment were not correlated with OS. Our findings merit further investigation of EBV + PCNSL tumors and EBV-directed therapies.

KW - Epstein-Barr virus (EBV)

KW - post-transplant Lymphoproliferative Disorders (PTLD)

KW - primary CNS lymphoma (PCNSL)

UR - http://www.scopus.com/inward/record.url?scp=85150971844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150971844&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2191152

DO - 10.1080/10428194.2023.2191152

M3 - Article

C2 - 36960939

AN - SCOPUS:85150971844

SN - 1042-8194

VL - 64

SP - 1026

EP - 1034

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 5

ER -

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this